Skip to main content

Advertisement

Table 3 Clinical down-staging effects of the FEC and PE regimens on locally advanced breast cancer

From: Weekly taxane–anthracycline combination regimen versus tri-weekly anthracycline-based regimen for the treatment of locally advanced breast cancer: a randomized controlled trial

T stage FEC arm [cases (%)] P value PE arm [cases (%)] P value
Baseline After NACT Baseline After NACT
Total 151 151 <0.001 142 142 <0.001
0 0 (0.00) 5 (3.31)   0 (0.00) 12 (8.45)  
1 0 (0.00) 46 (30.46)   0 (0.00) 62 (43.66)  
2 106 (70.20) 77 (50.99)   86 (60.65) 55 (38.73)  
3 43 (28.48) 9 (6.62)   52 (36.62) 5 (3.52)  
4 2 (1.32) 5 (2.65)   4 (2.82) 2 (1.41)  
Missing 0 (0.00) 9a (5.96)   0 (0.00) 6b (4.23)  
  1. FEC tri-weekly 5-fluorouracil–epirubicin–cyclophosphamide regimen, PE weekly paclitaxel–epirubicin regimen
  2. aOf the 9 patients, 2 had migrated to other cities and were not restaged, 5 declined further treatment and were not restaged, and 2 were lost to follow-up
  3. bOf the 6 patients, 5 declined further treatment and were not restaged, and 1 was lost to follow-up